HeartRhythm

MAY 14, 2024

The field of electrophysiology (EP) has benefited from numerous seminal innovations and discoveries that have enabled clinicians to deliver therapies and interventions that save lives and promote quality of life.

Electrophysiology 45

Electrophysiology Quality of Life Education Reimbursement 45

DAIC

JUNE 11, 2024

In electrophysiology, innovation is king, but it is often incremental, and it almost always lacks rationale, comprehensive clinical documentation and relevance for hospitals that try to balance the increasing costs of new technology with increasing demand and reimbursement that just can’t keep pace.

Innovation 104

Innovation AFIB Technology Electrophysiology 104

American College of Cardiology

FEBRUARY 1, 2025

In today's health care landscape, where quality metrics tied to reimbursement have become the standard, clinicians are under increasing pressure to prescribe specific medications. Clinicians working with older patients have witnessed firsthand how polypharmacy can complicate both their care and diminish quality of life.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40

DAIC

JANUARY 16, 2024

About the Carillon Mitral Contour System Many heart failure patients suffer from functional mitral regurgitation, which when left untreated, exacerbates their heart failure, further weakening the heart, degrading their quality of life, and reducing survival.

Bicuspid/Mitral 59

Bicuspid/Mitral Heart Failure Catheterization Laboratory Innovation 59

Wellnest

DECEMBER 18, 2023

Hence, to reduce the risk of CVDs, regular diagnosis using advanced tools like the , Wellnest 12L ECG Machine and modern therapies such as Renal Denervation for treatment is needed to improve the health and quality of life of individuals with resistant blood pressure.

Hypertension 52

Hypertension Blood Pressure Ablation Reimbursement 52

DAIC

JULY 25, 2024

BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

MARCH 13, 2024

CMS previously published a New Technology APC (Ambulatory Payment Classifications) code that covers the CardiAMP Cell Therapy investigational study procedure, including the BioCardia investigational products utilized to perform the study procedure, allowing the study centers to be reimbursed for the study procedure and products.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111